CCO Independent Conference Highlights of the European Society for Medical Oncology 2023 Congress *

Review a conference preview commentary on experts’ abstracts to watch, Capsule Summary slidesets, and an expert analysis of key studies from ESMO 2023.

Share

Program Content

Activities

ESMO 2023 Preview
An Expert’s Guide to ESMO 2023: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: October 19, 2023

View Activity
20 Capsule Summary Slidesets

Activities

HERTHENA-Lung01 CNS Analysis
HERTHENA-Lung01: Intracranial Results From a Phase II Trial of HER3-DXd in Previously Treated Patients With Advanced EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2023

View Activity
monarchE 5 yr update
monarchE 5-Yr Outcomes: Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2023

View Activity
LIBRETTO-431
LIBRETTO-431: Randomized Phase III Trial of First-line Selpercatinib vs Chemotherapy Plus Pembrolizumab in RET Fusion‒Positive NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2023

View Activity
TROPiCS-03 ES-SCLC Cohort
TROPiCS-03 Phase II Basket Trial: Sacituzumab Govitecan as Second-line Therapy for Extensive-Stage Small-Cell Lung Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2023

View Activity
ALINA
ALINA: Randomized Phase III Trial of Adjuvant Alectinib vs Chemotherapy in Patients With Stage IB-IIIA ALK-Positive NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

View Activity
MATTERHORN
MATTERHORN: Interim Results From a Phase III Trial of Durvalumab + FLOT in Resectable Gastric and Gastroesophageal Junction Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

View Activity
Neoadjuvant Cemiplimab for CSCC
1-Yr Follow-up of Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

View Activity
RELATIVITY-047 Biomarkers
RELATIVITY-047: Biomarker Analysis of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

View Activity
LIBRETTO-531
LIBRETTO-531: Phase III Trial of Selpercatinib vs Cabozantinib or Vandetanib in Patients With Advanced RET-Mutant Medullary Thyroid Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

View Activity
DAD Trial
Double Antibody–Drug Conjugate (DAD): Phase I Trial of Sacituzumab Govitecan + Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2023

View Activity
CheckMate 77T
CheckMate 77T: Phase III Trial of Neoadjuvant Nivolumab + Chemotherapy vs Placebo + Chemotherapy With Adjuvant Nivolumab or Placebo in Stage II-IIIB NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2023

View Activity
NICHE-3
NICHE-3: Phase II Trial of Neoadjuvant Nivolumab + Relatlimab for Locally Advanced dMMR Colon Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2023

View Activity
EMBER Imlunestrant in BC
EMBER: Phase Ia/b Study of Imlunestrant, a Next-Generation Oral SERD, in Advanced ER+/HER2- Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2023

View Activity
Alliance A021602/CABINET NETs
Alliance A021602/CABINET: Phase III Trial Evaluating Cabozantinib vs Placebo for Advanced Neuroendocrine Tumors After Disease Progression on 1 or More Therapies
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2023

View Activity
EV-302/KEYNOTE-A39
EV-302/KEYNOTE-A39: Phase III Trial of Enfortumab Vedotin + Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2023

View Activity
CheckMate 901
CheckMate 901 Phase III Trial: First-line Nivolumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin Alone for Unresectable/Metastatic Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2023

View Activity
TROPION-Breast01
TROPION-Breast01: Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+ HER2- Metastatic Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2023

View Activity
TROPION-Lung01
Phase III TROPION-Lung01: Datopotamab Deruxtecan vs Docetaxel for Previously Treated Advanced or Metastatic NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2023

View Activity
DESTINY-Breast T-DXd Brain Mets
Trastuzumab Deruxtecan for Brain Metastases in HER2-Positive Metastatic Breast Cancer: A Pooled Analysis of DESTINY-Breast01, 02, and 03 Trials
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 01, 2023

View Activity
DESTINY-PanTumor01
DESTINY-PanTumor01: Phase II Study of Trastuzumab Deruxtecan in Patients With HER2-Activating Mutations in Solid Tumors
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 01, 2023

View Activity

Activities

ESMO 2023 Highlights
Key Studies in Breast, Lung, Gastrointestinal, Genitourinary, and Skin Cancers: CCO Independent Conference Highlights of the 2023 ESMO Congress
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2023

Expires: December 21, 2024

View Activity

Faculty

cover img faculity

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

cover img faculity

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

John Marshall, MD

Executive Director 
Medstar Hematology/Oncology
Director
Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

cover img faculity

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.